T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs

Fc receptor nonbinding anti-CD3 monoclonal antibodies show promise for clinical application, in that they suppress graft rejection without the toxicity associated with conventional anti-CD3 antibody therapy. Recent studies suggest that the mechanism of soluble anti-CD3 antibody mediated immunosuppression involves partial signaling, induced cytokine deviation and Th1 cell inactivation.